SecBot SecBot
SECBOTREPLAY Home › Report › RARE

RARE · Ultragenyx announced that its Phase 3 Aspire study for apazunersen…

Ultragenyx Pharmaceutical Inc. · 8-K filed Sep 2, 2026 at 16:04 ET

At the news

BEARISHIMPACT 8/10

8-K filed Sep 2, 2026 at 16:04 ET

Ultragenyx announced that its Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome failed to meet the primary endpoint (Bayley-4 cognitive raw score) and the key secondary endpoint (MDRI). The company will evaluate the program's disposition and implement significant expense reductions while supporting its commercial business. This is a major pipeline setback for a company with a $2.5B market cap that was likely pricing in some probability of success for this high-profile asset.

  • Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score.
  • The study also failed the key secondary endpoint of net response in Multidomain Responder Index (MDRI).
  • No differences were observed between treated and control groups supporting efficacy in Bayley Cognition raw scores or MDRI.
  • Safety profile was consistent with Phase 1/2.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access